**2020**  
**Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma**  
Sriskandarajah, P., De Haven Brandon, A., MacLeod, K., Carragher, N.O., Kirkin, V., Kaiser, M. & Whittaker, S.R.  
30 Mar 2020, BMC Cancer. 20, 1  
https://pubmed.ncbi.nlm.nih.gov/32228485/

**2019**  
**A Synergistic Anti-Cancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical-Genetic High-Content Phenotypic Screen**  
Dawson, J., Serrels, B., Byron, A., Muir, M., Makda, A., Garcia-Munoz, A., Von Kriegsheim, A., Lietha, D., Carragher, N. & Frame, M.  
29 Nov 2019, Molecular Cancer Therapeutics.  
https://pubmed.ncbi.nlm.nih.gov/31784455/

**N-cadherin stabilises neural identity by dampening anti-neural signals**  
Punovuori, A., Migueles, R.P., Malaguti, M., Blin, G., MacLeod, K.G., Carragher, N., Pieters, T., van Roy, F., Stemmler, M.P. & Lowell, S.  
10 Oct 2019, Development.  
https://pubmed.ncbi.nlm.nih.gov/31601548/

**Mauritian Endemic Medicinal Plant Extracts Induce G2/M Phase Cell Cycle Arrest and Growth Inhibition of Oesophageal Squamous Cell Carcinoma in Vitro**  
Rummun, N., Hughes, R.E., Beesoo, R., Li, W.W., Aldulaimi, O., MacLeod, K., Bahorun, T., Carragher, N., Kagansky, A. & Neerghleen-bhujun, V.S.  
15 Apr 2019, ACTA NATURE. 11, 1  
https://pubmed.ncbi.nlm.nih.gov/31024752/

**2018**  
**Reversal of proliferation deficits caused by chromosome 16p13.11 microduplication through targeting NFκB signaling: an integrated study of patient-derived neuronal precursor cells, cerebral organoids and in vivo brain imaging**  
Johnstone, M., Vasistha, N.A., Barbu, M.C., Dando, O., Burr, K., Christopher, E., Glen, S., Robert, C., Fetit, R., Macleod, K.G., Livesey, M.R., Clair, D.S., Blackwood, D.H.R., Millar, K., Carragher, N.O., Hardingham, G.E., Wyllie, D.J.A., Johnstone, E.C., Whalley, H.C., McIntosh, A.M. & 2 others.  
6 Nov 2018, Molecular Psychiatry.  
https://pubmed.ncbi.nlm.nih.gov/30401811/

**2017**  
**Pharmaco-genomic investigations of organo-iridium anticancer complexes reveal novel mechanism of action**  
Hearn, J.M., Hughes, G.M., Romero-Canelón, I., Munro, A., Rubio Ruiz, B., Liu, Z., Carragher, N. & Sadler, P.J.  
13 Nov 2017, Metallomics.  
https://pubmed.ncbi.nlm.nih.gov/29131211/
TRPA1-FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p
Berrout, J., Kyriakopoulou, E., Moparthi, L., Hogaia, S.A., Berrout, L., Ivan, C., Lorger, M., Boyle, J., Peers, C., Muench, S., Elies Gomez, J., Hu, X., Hurst, C., Hall, T., Umamaheswaran, S., Wesley, L., Gagea, M., Shires, M., Manfield, I., A. Knowles, M., Davies, S., Suhling, K., Teijeiro Gonzalez, Y.T., Carragher, N., Macleod, K., Abbott, N.J., Calin, G.A., Gamper, N., Zygmunt, P.M. & Timsah, Z.
16 Oct 2017, Nature Communications.
https://pubmed.ncbi.nlm.nih.gov/29038531/

Broad-Spectrum Inhibition of Respiratory Virus Infection by MicroRNA Mimics Targeting p38 MAPK Signaling.
McCaskill, J.L., Ressel, S., Alber, A., Redford, J., Power, U.F., Schwarze, J., Dutia, B.M., Buck, A.H.
2017 Jun 16, Mol Ther Nucleic Acids; 7:256-266. KM and NC acknowledged
https://pubmed.ncbi.nlm.nih.gov/28624201/

Global histone modification fingerprinting in human cells using epigenetic reverse phase protein array
Partolina, M., Thoms, H.C., Macleod, K.G., Rodriguez-blanco, G., Clarke, M.N., Venkatasubramani, A.V., Beesoo, R., Larionov, V., Neergheen-bhujun, V.S., Serrels, B., Kimura, H., Carragher, N.O. & Kagansky, A.
14 Mar 2017, Cell Death Discovery. 3, p. 16077
https://pubmed.ncbi.nlm.nih.gov/28326191/

2016
Naturally Inspired Peptide Leads: Alanine Scanning Reveals an Actin-Targeting Thiazole Analogue of Bisebromoamide
Johnston, H.J., Boys, S.K., Makda, A., Carragher, N.O. & Hulme, A.N.
5 Aug 2016, ChemBioChem. 17, 17, p. 1621-1627
https://pubmed.ncbi.nlm.nih.gov/27304907/

Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.
Creedon, H., Gómez-Cuadrado, L., Tarnauskaité, Ž., Balla, J., Canel, M., MacLeod, K.G., Serrels, B., Fraser, C., Unciti-Broceta, A., Tracey, N., Le Bihan, T., Klinowska, T., Sims, A.H., Byron, A., & Brunton, V.G.
8 Mar 2016, Oncotarget 7(10), 11539-11552
https://pubmed.ncbi.nlm.nih.gov/26883193/

2015
FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis
Qian, B., Zhang, H., Li, J., He, T., Yeo, E-J., Soong, D.Y H., Carragher, N.O., Munro, A., Chang, A., Bresnick, A.R., Lang, R.A. & Pollard, J.W.
10 Aug 2015, Journal of Experimental Medicine. 212, 9
https://pubmed.ncbi.nlm.nih.gov/26261265/
Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells
Hearn, J.M., Romero-Canelón, I., Munro, A.F., Fu, Y., Pizarro, A.M., Garnett, M.J., McDermott, U., Carragher, N.O. & Sadler, P.J.
21 Jul 2015, Proceedings of the National Academy of Sciences. 112, 29, p. E3800-5
https://pubmed.ncbi.nlm.nih.gov/26162681/

2014
Extracellular palladium-catalysed dealkylation of 5-fluoro-1-propargyl-uracil as a bioorthogonally activated prodrug approach
Weiss, J.T., Dawson, J.C., Macleod, K.G., Rybski, W., Fraser, C., Torres-Sanchez, C., Patton, E.E., Bradley, M., Carragher, N.O. & Unciti-Broceta, A.
13 Feb 2014, Nature Communications. 5, 3277.
https://pubmed.ncbi.nlm.nih.gov/24522696/

2013
Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells
Gattelli, A., Nalvarte, I., Boulay, A., Roloff, T.C., Schreiber, M., Carragher, N., Macleod, K., Schlederer, M., Lienhard, S., Kenner, L., Torres-Arayus, M.I. & Hynes, N.E.
Sep 2013, EMBO molecular medicine. 5, 9, p. 1335-1350
https://pubmed.ncbi.nlm.nih.gov/23868506/

Dasatinib inhibits mammary tumour development in a genetically engineered mouse model
Karim, S., Creedon, H., Patel, H., Carragher, N.O., Morton, J., Muller, W., Evans, T., Gusterson, B., Sansom, O. & Brunton, V.
Aug 2013, The Journal of Pathology. 230, 4, p. 430-440
11 https://pubmed.ncbi.nlm.nih.gov/23616343/

Book Chapters & Review Articles

Drug Screening Platforms and RPPA
Dawson, J.C., Warchal, S.J. & Carragher, N.O.
10 Dec 2019, Reverse Phase Protein Arrays; vol. 1188
https://pubmed.ncbi.nlm.nih.gov/31820390/

Reverse Phase Protein Arrays and Drug Discovery
Macleod, K.G., Serrels, B. & Carragher, N.O.
15 Aug 2017, Proteomics for Drug Discovery; vol. 1647
https://pubmed.ncbi.nlm.nih.gov/28809001/

Reverse Phase Protein Arrays elucidate mechanisms-of-action and phenotypic response in 2D and 3D models
Pawlak, M. & Carragher, N.O.
30 May 2017, Drug Discovery Today: Technologies.
https://pubmed.ncbi.nlm.nih.gov/28647089/
Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report
Akbani, R., Becker, K-F., Carragher, N., Goldstein, T., de Koning, L., Korf, U., Liotta, L., Mills, G.B., Nishizuka, S.S., Pawlak, M., Petricoin, E.F., Pollard, H.B., Serrels, B. & Zhu, J.
Jul 2014, Molecular and Cellular Proteomics. 13, 7, p. 1625-1643
https://pubmed.ncbi.nlm.nih.gov/24777629/

Quantitative phenotypic and pathway profiling guides rational drug combination strategies
Dawson, J. & Carragher, N.O.
28 May 2014, Frontiers in pharmacology. 5
https://pubmed.ncbi.nlm.nih.gov/24904421/

Combining imaging and pathway profiling: an alternative approach to cancer drug discovery.
Carragher, N., Brunton, V. & Frame, M.
Mar 2012, Drug Discovery Today. 17, 5-6, p. 203-214
https://pubmed.ncbi.nlm.nih.gov/22493783/